BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
Go back to BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting| BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) | Delayed: 8.81 -0.26 (2.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.07 | 52 Week High | $10.98 | |||
| Open | $9.07 | 52 Week Low | $1.63 | |||
| Day High | $9.23 | P/E | N/A | |||
| Day Low | $8.80 | EPS | $-0.68 | |||
| Volume | 5,152,522 | |||||
